Head & Neck Cancer
950,000
new diagnoses worldwide each year
400,000
deaths worldwide each year
APG-157 development programs
Aveta is advancing APG-157 across clinical and preclinical programs in cancers where reprogramming the tumor immune microenvironment may offer a new therapeutic approach.
Program
Indication
PreclinicalPhase 1Phase 2Phase 3
Study
APG-157
Newly Diagnosed Locally Advanced
Head and Neck Cancer
FDA Fast Track DesignationFDA Orphan Drug Designation
Head and Neck Cancer
FDA Fast Track DesignationFDA Orphan Drug Designation
APG-126
Triple Negative Breast Cancer
APG-126
Diffuse Intrinsic Pontine Glioma (DIPG)
Development stage reflects the most advanced study for each indication.
High Grade Glioma
300,000–335,000
new diagnoses worldwide each year
220,000–250,000
deaths worldwide each year
Oral Dysplasia
An opportunity to intervene before invasive cancer develops.
Oral dysplasia is a precancerous condition that can progress to invasive oral cancer.